ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 May 2017
Last Updated on 18 Jan 2021
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Golimumab 50 mg/0.5 ml and 100 mg/ml pre-filled syringes in line with their registered indications for treating adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and ulcerative colitis.

Subsidy status
Golimumab 50mg/0.5ml and 100 mg/ml pre-filled syringes are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. 

Golimumab should be used in line with the clinical criteria in the checklists for MAF applications for anti-TNFα biologics.

MAF subsidy does not apply to golimumab 12.5mg/1ml concentrate solution for infusion formulation.

Golimumab for treating RA, PsA, AS, NR axial spondyloarthritis and UC (updated 18 Jan 2021)